Over the last decade, it has gradually been replaced by the GnRH antagonist protocol, which is characterized by immediate suppression of LH with fewer injections and lower risk of ovarian hyperstimulation syndrome (OHSS) [2]. This evidence concerns the gene PLOD1 and ovarian hyperstimulation syndrome.